AR and neoplasm: Co‐targeting the AR (with ENZ) and molecular chaperone CLU (with OGX‐011) repressed ENZ‐induced activation of AKT and MAPK pathways, accelerated AR degradation and repressed AR transcriptional activity through mechanisms involving decreased YB‐1‐regulated expression of the AR co‐chaperone, FKBP52, which synergistically delayed CRPC LNCaP tumor progression in vivo (Matsumoto et al, 2013).